For passing PH3 efficacy alone, SP should jump to near 40 cents. Looking at the CR, it is discounted but bringing in institution investors can attract more fund to enter. It could push it higher and higher in long run.
Ann: Dimerix Completes $20M Placement, page-8
-
- There are more pages in this discussion • 146 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
55.0¢ |
Change
-0.060(9.84%) |
Mkt cap ! $302.3M | |||
| Open | High | Low | Value | Volume |
| 60.5¢ | 61.0¢ | 55.0¢ | $2.309M | 4.010M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 137019 | 55.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.5¢ | 22500 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |